西安交通大学学报（医学版）2026，Vol.47Issue(1)：39-47,9.DOI:10.7652/jdyxb202601006
阿尔茨海默病Aβ免疫治疗患者的综合管理
Comprehensive management of Alzheimer's disease patients treated with Aβ immunotherapy
摘要
Abstract
Although the monoclonal antibodies targeting Aβ(β-amyloid),lencanemab and donanemab,have ushered in a new era of disease-modifying therapy(DMT)for Alzheimer's disease(AD),AD remains a complex pathological process.Patients receiving monoclonal antibody immunotherapy require comprehensive management.This article systematically reviews the general care,cognitive function improvement,behavioral symptom control,non-pharmacological interventions,and multidisciplinary comprehensive management mode of Aβ immunotherapy.It aims to provide clinicians with comprehensive management strategies based on evidence-based medicine.关键词
阿尔茨海默病(AD)/β-淀粉样蛋白(Aβ)/Aβ免疫治疗/综合管理Key words
Alzheimer's disease(AD)/β-amyloid(Aβ)/Aβ immunotherapy/comprehensive management分类
医药卫生引用本文复制引用
赵春梅,许贤瑞,李晓聪,张庆..阿尔茨海默病Aβ免疫治疗患者的综合管理[J].西安交通大学学报（医学版）,2026,47(1):39-47,9.基金项目
2023宁夏自然科学基金项目(重点项目)(No.2023AAC0206)Supported by Ningxia Natural Science Foundation Project(No.2023AAC0206) （重点项目）
